Abstract. Paired helical filaments, the main structural components of the neurofibrillary tangles in Alzheimer disease, consist of phosphorylated tau protein. Because the levels and degree of phosphorylation are significantly higher in paired helical filament (PHF)-derived tau than in normal adult tau, and because phosphorylation of tau severely disrupts microtubule stability, it is postulated that tau phosphorylation is an important step in PHF formation. The kinases and/or phosphatases that act in vivo to help induce such a pathological state of tau, however, are not yet known. In this study we implicate the non-proline directed kinase MARK in PHF-tau phosphorylation, by virtue of its close intermolecular association with the phosphorylated Ser262 epitope on PHF-tau as assessed by fluorescence resonance energy transfer. Moreover, because this tight enzymesubstrate association is observed in neurofibrillary tangles in Alzheimer tissue, we suggest that PHF-tau phosphorylation may occur to some extent on assembled PHF filaments.
INTRODUCTION
Abnormally phosphorylated tau is the predominant component of the paired helical filaments (PHFs) of Alzheimer neurofibrillary tangles (NFTs). Because NFT burden has been correlated with severity of clinical dementia (1), the events leading to PHF formation are of primary interest to our understanding of Alzheimer disease (AD). Tau derived from PHFs are phosphorylated at more than 20 sites, some of which are present (albeit at a lower level) in normal adult tau (2) (3) (4) . Upon phosphorylation, tau, a class of microtubule (MT)-associated proteins, dissociates from the MT network and thus loses its ability to stabilize microtubules (5, 6) . Phosphorylation of tau, therefore, may mediate axonal MT disruption, leading to PHF formation and neuronal degeneration characteristic of AD.
Among the phosphorylation sites, Ser262 is noteworthy because it is located in the microtubule-binding repeat region on tau, thought to be the site of tau attachment to microtubules, as well as of tau self-polymerization (7, 8) . Ser262 is the non-proline directed site of the first of 4 KXGS motifs in the tau MT-binding repeat domain; the KXGS motif of the fourth repeat, Ser356, is the only other site in the MT-binding domain found to be phosphorylated in PHF-tau (9) . In contrast to tau phosphorylation at sites located in the amino and carboxy termini that flank the MT-binding domain, phosphorylation of tau at Ser262 virtually abolishes tau binding to MTs and disrupts MT stability (10, 11) . In addition, Ser262 is highly phosphorylated in PHF-tau, in contrast to limited phosphorylation levels in normal adult or fetal tau (12) (13) (14) (15) . Because phosphorylation at Ser262 seems particularly specific for PHFs, as well as detrimental to tau-MT dynamics, the identification of its kinase may be helpful in understanding PHF-tau formation. Microtubule-affinity regulating kinase (MARK), a Ser/ Thr110kD kinase expressed ubiquitously in brain, phosphorylates tau in vitro at Ser262 and, with less affinity, Ser356, Ser293, and Ser324 (10, 11) . These phosphorylation sites correspond to the KXGS sequences of the first, fourth, second and third repeats, respectively, in the MT-binding region of tau. This kinase also phosphorylates homologous domains in other microtubule associated proteins, MAP2 and MAP4 (16) . Transfection of MARK in cell cultures results in dramatic microtubule instability, disorganization of the microtubule array and eventually, cell death (10, 11) . This suggests that the kinase, via tau phosphorylation at these sites, is an important regulator of tau-MT binding. Thus MARK is an excellent candidate for a PHF-associated kinase.
We have recently developed use of fluorescence resonance energy transfer (FRET), a biophysical technique that allows estimation of a close intermolecular association on the order of 10 nm, for immunohistochemical assessment of protein-protein interactions. Using FRET, we have demonstrated a close interaction between activated MAP kinase and its putative phosphorylation sites on PHF-tau, Ser199/202, and Ser396/404 (17) . In this study, we use immunohistochemical techniques and FRET to test the hypotheses that MARK is expressed in neurons that develop NFT, and that MARK is specifically associated with its putative phosphorylation site, Ser262, on PHF-tau.
MATERIALS AND METHODS

Tissue Processing
Immunohistochemistry was performed on 6 cases of patients with the clinical diagnosis and neuropathological confirmation of AD and 3 cases of age-matched normal controls (postmortem interval for all tissues Ͻ24 h) (18) . Tissue was obtained from the Massachusetts Alzheimer's Disease Research Center Brain Bank (Dr. E. T. Hedley-Whyte, Director). The temporal lobe was fixed in 4% paraformaldehyde-lysine-metaperiodate for 36 to 48 h at 4ЊC, then cryoprotected in 10% glycerol in tris buffered saline (pH 7.4), and cut using a freezing sledge microtome at 50 m thickness. Individual sections were stored in cryoprotective solution at Ϫ20ЊC until immunostaining.
Immunohistochemistry
Tissue was permeablized with 0.5% Triton X-100 in 0.05 M tris buffered saline solution (TBS) for 20 min and blocked in 3% milk in 0.05 M TBS for 1 h. Tissue was then treated with primary antibodies diluted in 1.5% normal goat serum in 4ЊC overnight, followed by 1 h incubation with appropriate secondary antibodies in 1.5% normal goat serum. The following primary antibodies were used: PHF-1, a phosphorylation-dependent monoclonal antibody that recognizes PHF-tau at the pSer396/pSer404 sites (19, 20) (courtesy of Dr. Peter Davies, Albert Einstein College of Medicine, Bronx, NY); 12E8, a monoclonal antibody that recognizes PHF-tau at site pSer262 (15) (courtesy of Dr. Peter Seubert, Elan Pharmaceuticals); 10E4, a mouse-IgM antibody against heparan sulfate (Seikagaku Corporation, Tokyo, Japan); anti-MARK1 polyclonal raised against purified, recombinant MARK (11); monoclonal anti-synaptophysin (SY38, Boehringer-Mannheim; SVP-38, Sigma, St. Louis, MO); and monoclonal anti-GFAP (DAKO, Carpinteria, CA). MARK immunostaining was detected with peroxidase reaction, using diaminobenzidine as chromagen. For double staining experiments and for FRET experiments with the BioRad 1024 Confocal microscope, the tissues were labeled with fluorescent secondary antibodies, tetramethylrhodamine anti-mouse or anti-rabbit, and fluorescein (FITC) anti-mouse or anti-rabbit (Jackson ImmunoResearch, West Grove, PA).
Fluorescence Resonance Energy Transfer
FRET describes a non-radiative transfer of energy between 2 fluorophores that are extremely close to one another (within about 10 nm), if the emission spectra of the donor fluorophore overlaps the excitation maxima of the acceptor molecule. The efficiency of energy transfer, E, is inversely proportional to the sixth power of the distance between the 2 fluorochromes, R, according to the equation E ϭ R o 6 /(R 6 ϩR o 6 ). E is measured as the fraction decrease in donor fluorescence as a result of energy transfer to an acceptor, or E ϭ 1ϪD A /D, where D A is the fluorescence intensity of the donor (e.g. FITC) in the presence of the acceptor (e.g. rhodamine) and D is the donor fluorescence intensity alone. Thus E approaches a value of 1.0 with 100% FRET, and a value of 0.0 in the absence of FRET. The quantity Fig. 2 . FRET is observed between anti-MARK1 and 12E8. Neurofibrillary tangle immunostained against (a) the 12E8 epitope, pSer262, with rhodamine secondary antibody (excited with 568 nm light and emission filter at 605 nm), and (b) anti-MARK1 with fluorescein secondary antibody (excited at 488 nm and emission filter at 522 nm). FRET was determined by bleaching the rhodamine acceptor molecule in a discrete area of colocalization (box) using localized high power 568 nm light. Image (c) shows the area of photobleaching (excited at 568 nm, emitted at 605 nm) and (d) shows the resultant increase in the donor fluorescein fluorescence (excited at 488 nm and emitted at 522 nm) observed only in the region in which rhodamine was destroyed. FRET is measured by the marked increase in donor fluorescence intensity in this discrete region, as compared with the donor fluorescence in this region before photobleaching (b). Scale bar ϭ 10 m.
R o , characteristic of the properties of the fluorophores, is the distance at which there is 50% energy efficiency, and for the fluorescein-rhodamine pair R o has been experimentally found to be 4.5-5.5 nm (21, 22) . Because the amount of FRET is inversely proportional to the sixth power of the distance between fluorophores, FRET cannot be detected if the distance is greater than about 10 nm. The distances calculated between fluorophores are an estimate of the distance between epitopes. Because we used an indirect immunofluorescent technique, and since the size of an antibody molecule is about 11.5 nm (21), we estimate that the maximum distance between epitopes that can show FRET is Ͻ50 nm. This improves by at least an order of magnitude the resolution possible with confocal microscopy, which is on the order of ϳ500 nm.
RESULTS
Immunohistochemical staining in temporal cortices of normal control patients reveals weak anti-MARK staining in the cytoplasm of neurons (Fig. 1) . In contrast, we observed increased staining of MARK in the temporal lobe of Alzheimer cases relative to normal control cases; this increased staining was associated with NFTs. For example, anti-MARK immunostaining colocalized with PHFtau as stained with 12E8 and PHF-1. MARK showed no association with astrocytes or synaptic vesicles as assessed by double staining with antibodies directed against MARK and against glial fibrillary acidic protein or synaptophysin.
In vitro, MARK preferentially phosphorylates tau at Ser262. The monoclonal antibody 12E8 specifically recognizes tau phosphorylated at this site (15) . We therefore postulated that MARK/PHF colocalization might reflect an inter-molecular association of MARK with tau containing pSer262. We used FRET to further explore the colocalization of anti-MARK staining with PHF-tau antibodies. Our application of FRET, acceptor photobleaching, exploits the fact that in the presence of acceptor, some of the donor fluorescence energy may be transferred to the acceptor, thus decreasing the maximal donor fluorescence emission. Photobleaching the acceptor destroys this transfer of energy, resulting in an increase in observed fluorescence emission of the donor.
When we photobleached rhodamine in a discrete area of MARK and 12E8 colocalization (Fig. 2) , the donor fluorescence intensity of fluorescein almost quadrupled (Table) in comparison to the intensity before photobleaching (D A /D ϭ 0.26). This increase was strictly confined to the region of acceptor photobleaching, and was independent of which antibody, MARK or 12E8, was attached to which fluorochrome, rhodamine or fluorescein. In contrast, photobleaching with 568 nm light a singlelabel tissue sample, or in singly labeled neurons (for example, only stained with MARK or with 12E8), did not result in a similar increase in fluorescein fluorescence. These results suggest that the increase in donor fluorescence reflects FRET between the fluorophores. The Fig. 3 . FRET is not observed between 12E8 and heparan sulfate. Neurofibrillary tangle is immunostained with (a) 12E8 (rhodamine: 568 nm excitation, 605 nm emission) and (b) antiheparan sulfate (10E4; 488 nm excitation, 522 nm emission). In (c), the rhodamine is photobleached by 568 nm light in the discrete area, but as shown in (d), the donor fluorescence intensity does not increase in the discrete area, indicating the absence of FRET between 12E8 and heparan sulfate. Scale bar ϭ 10 m. demonstration by this method of a very close intermolecular association (i.e. at distances allowing FRET) between MARK and pSer262 suggests that Ser262 may be phosphorylated by MARK in vivo in AD brain.
The FRET experiment was also performed on tissue samples stained with anti-MARK and PHF-1 ( Table) . We found that the donor fluorescence intensity on average doubled in the absence of acceptor relative to the donor intensity in the presence of acceptor (D A /D ϭ 0.49). This suggests that although the phosphorylated sites on tau recognized by PHF-1, Ser-396 and Ser-404, are not putative substrates for MARK, there is also a close molecular interaction between MARK and the epitopes recognized by PHF-1 in Alzheimer tissue.
Heparan sulfate, a sulphated glycoaminoglycan, colocalizes with NFTs (23) (24) (25) ; it is one of relatively few non-tau molecules that show consistent immunostaining of NFTs. It has been postulated that heparan sulfate facilitates aggregation of PHFs by binding to tau and inducing a conformational change in tau and/or by activating tau kinases (26) (27) (28) (29) . Antibodies against heparan sulfate and the pSer262 site on tau (10E4 and 12E8, respectively) show colocalization in Alzheimer brain using standard confocal microscopy ( Fig. 3) . However, we found only weak FRET as detected by acceptor photobleaching in this double-labeled sample (Table) . While epitope and antibody orientations may diminish or preclude FRET, these consistent observations suggest that the MARK-pSer262 interaction is quite strong compared with other interacting proteins.
DISCUSSION
The colocalization of MARK staining with PHF-tau antibodies and the presence of MARK immunostaining in neuronal populations vulnerable to NFT formation suggest that this kinase may be directly involved in abnormal tau phosphorylation in Alzheimer brain. Phosphorylation at Ser262, MARK's main site of activity on tau, has been shown to dramatically reduce tau's affinity for microtubules (5); our in vivo data reinforces in vitro studies that implicate MARK in Ser262 phosphorylation, and support the notion that MARK mediated tau phosphorylation is an abnormal event in Alzheimer pathology.
We demonstrate FRET between MARK and PHF-tau at sites Ser262 and Ser396/404, using antibody 12E8 and PHF-1, respectively. The exact distances among these epitopes must be interpreted with caution given the indirect immunofluorescence technique we used, but nonetheless imply a close molecular interaction between MARK and tau in NFTs. Biochemical evidence shows that MARK phosphorylates the non-proline directed KXGS motifs of the MT-binding domain, but not the proline-directed Ser396/404 site. The observation of FRET between MARK and PHF-1 suggests some intermolecular interaction between these 2 epitopes. One interpretation of this data is that the FRET is a result of the conformational orientation of tau within the PHF structure which brings the Ser396/404 site on tau (near tau's carboxy terminus) in proximity with the kinase directed to a spatially neighboring site on tau.
Phosphorylation of tau at Ser262 has recently been shown to not only inhibit microtubule association, but also to inhibit tau aggregation in vitro (30) . If pSer262 inhibits tau aggregation, it is puzzling that PHF-tau contains prominent pSer262 immunoreactivity. Our current data demonstrates a close intermolecular association of pSer262 with MARK in Alzheimer brain PHF-tau, suggesting that Ser262 on tau is phosphorylated, at least in part, on intact, already formed PHF. Taken together with similar observations on the association of PHF-tau with other kinases, including activated MAPK, glycogen synthase kinase 3ß, cyclin dependent kinase 5, tau protein kinase II, and PKN (17, (31) (32) (33) (34) (35) , we suggest that assembled PHF-tau may be a substrate for multiple kinases.
